scholarly journals Glucagon-like peptide 1 and fatty acids amplify pulsatile insulin secretion from perifused rat islets

2003 ◽  
Vol 369 (1) ◽  
pp. 173-178 ◽  
Author(s):  
Barbara A. CUNNINGHAM ◽  
Ann-Marie T. RICHARD ◽  
Joseph S. DILLON ◽  
Jennifer T. DALEY ◽  
Vildan N. CIVELEK ◽  
...  

Glucose-induced insulin secretion from isolated, perifused rat islets is pulsatile with a period of about 5—10min, similar to the insulin oscillations that are seen in healthy humans but which are impaired in Type II diabetes. We evaluated the pattern of enhancement by the potent incretin, glucagon-like peptide 1 (GLP-1). GLP-1 increased the amplitude of pulses and the magnitude of insulin secretion from the perifused islets, without affecting the average time interval between pulses. Forskolin and the phosphodiesterase inhibitor isobutylmethylxanthine had the same effect, suggesting that the effect was due to elevated cAMP levels. The possibility that cAMP might enhance the amplitude of pulses by reducing phosphofructo-2-kinase (PFK-2) activity was eliminated when the liver isoform of PFK-2 was shown to be absent from β-cells. The possibility that cAMP enhanced pulsatile secretion, at least in part, by stimulating lipolysis was supported by the observations that added oleate had a similar effect on secretion, and that the incretin effect of GLP-1 was inhibited by the lipase inhibitor orlistat. These data show that the physiological incretin GLP-1 preserves and enhances normal pulsatile insulin secretion, which may be essential in proposed therapeutic uses of GLP-1 or its analogues.

Metabolism ◽  
2000 ◽  
Vol 49 (12) ◽  
pp. 1579-1587 ◽  
Author(s):  
Seamus K. Sreenan ◽  
Anshu A. Mittal ◽  
Flora Dralyuk ◽  
William L. Pugh ◽  
Kenneth S. Polonsky ◽  
...  

2016 ◽  
Vol 101 (6) ◽  
pp. 2405-2414 ◽  
Author(s):  
Jenny Tong ◽  
Harold W. Davis ◽  
Amalia Gastaldelli ◽  
David D'Alessio

Abstract Objectives: Administration of ghrelin inhibits the acute insulin response to glucose and worsens IV glucose tolerance in healthy subjects. Evidence from preclinical studies suggests that ghrelin may have differential effects on glucose metabolism during fasting and feeding. Our objective was to test the effects of ghrelin on glucose and insulin responses during a meal tolerance test. Design: Acyl ghrelin (0.26 and 2.0 μg/kg/h) or saline was infused in 13 healthy subjects on three separate occasions in randomized order. Ghrelin was infused for 45 minutes to achieve steady-state levels and continued for 240 minutes after ingestion of a liquid test meal. Primary outcomes were area under the curve for glucose and insulin secretion. Results: We found that ghrelin infusions of 0.26 and 2.0 μg/kg/h raised steady-state plasma total ghrelin levels to 1.7- and 4.8-fold above fasting concentrations, but did not alter fasting plasma glucose or insulin levels. During the meal tolerance test, ghrelin decreased insulin sensitivity, impaired β-cell function, and induced glucose intolerance. The high-dose ghrelin infusion also raised postprandial glucagon like peptide 1 secretion without affecting glucose dependent insulinotropic polypeptide, glucagon, or peptide YY concentrations. Conclusions: We conclude that both physiologic and pharmacologic doses of ghrelin worsen the glucose and β-cell responses to meal ingestion in healthy humans. The increase in postprandial glucagon like peptide 1 secretion by ghrelin suggests a novel enteroendocrine connection, but does not mitigate the glucose intolerance.


Diabetes ◽  
1998 ◽  
Vol 47 (1) ◽  
pp. 45-49 ◽  
Author(s):  
N. Porksen ◽  
B. Grofte ◽  
B. Nyholm ◽  
J. J. Holst ◽  
S. M. Pincus ◽  
...  

Diabetes ◽  
1998 ◽  
Vol 47 (1) ◽  
pp. 45-49 ◽  
Author(s):  
N. Porksen ◽  
T. Grofte ◽  
B. Nyholm ◽  
J. J. Holst ◽  
S. M. Pincus ◽  
...  

2001 ◽  
Vol 7 (1) ◽  
pp. 35-44 ◽  
Author(s):  
Heather Gappa ◽  
Miroslav Baudyš ◽  
Jae Joon Koh ◽  
Sung Wan Kim ◽  
You Han Bae

Sign in / Sign up

Export Citation Format

Share Document